Multi-Cancer Blood Test: What It Costs and How to Get One
A multi-cancer blood test needs a clinician order and is rarely covered by insurance. Here is what drives the price and how to get one through Mito's telehealth path.
Medically reviewed by Rhonda Collins, FNP-C | Mito Health on August 27, 2026.
A multi-cancer early detection (MCED) blood test is a prescription test, so the first thing to know about getting one is that you cannot simply add it to a cart and skip the clinician. A doctor has to order it. The second thing to know is that price varies by how many cancers the panel screens for, and insurance usually does not cover these tests yet, though HSA and FSA funds often can. This article explains what drives the cost, what the coverage reality actually is, and the practical steps to order one. For current pricing on Mito’s three LucenceINSIGHT panels, check the product pages, because those numbers change and this article does not quote them.
What is a multi-cancer blood test?
A multi-cancer blood test looks for signals of several cancers at once from a single blood draw. LucenceINSIGHT, the MCED test Mito offers, uses next-generation sequencing to detect circulating tumor DNA (ctDNA) and cancer-associated viral DNA in the blood, then applies machine learning to predict the likely tissue of origin if a signal is found. The idea is a “signal to tissue of origin” readout: not only whether something looks off, but where to look next.
It is important to frame what this is and is not. An MCED test is a screening tool, not a diagnosis. It is an adjunct to guideline-recommended screening such as mammography, colonoscopy, and low-dose CT for eligible smokers. It does not replace them. A negative or low result does not mean you are cancer-free, and a positive result is not a diagnosis. A positive signal calls for a confirmatory clinical workup ordered by your doctor. LucenceINSIGHT is a prescription-only laboratory-developed test, not an FDA-cleared device.
For the full explainer on how these tests work and what the evidence shows, see the multi-cancer early detection test guide and the overview of what a multi-cancer early detection test is.
Why screen with a blood test at all?
Cancer is the second leading cause of death worldwide, according to the World Health Organization. Yet the majority of cancer deaths in the United States come from cancers that have no recommended screening test at all. Deriving from GLOBOCAN 2024 incidence and mortality data and the list of cancers with a U.S. Preventive Services Task Force screening recommendation, over half of US cancer deaths fall outside routine screening programs. Late diagnosis is common: one analysis found that 52.8% of cancers are diagnosed at a late stage, Stage III or IV (Zeng H et al., Lancet 2021). Because five-year survival is generally much higher when cancer is caught early, per NIH National Cancer Institute SEER data, a blood-based test that widens the net beyond the handful of screenable cancers is the gap MCED is trying to address.
None of this makes MCED a replacement for proven screening. It is an addition for the cancers that current programs miss.
What affects the price of a multi-cancer blood test?
Several real cost drivers sit behind an MCED test, which is why it is priced well above a routine blood panel:
- Advanced sequencing. These tests run deep next-generation sequencing to detect ctDNA and viral DNA that may be present at very low levels in the bloodstream. That sequencing depth and the reagents behind it are expensive.
- Machine-learning analysis. Detecting a signal is only half the job. Predicting the likely tissue of origin uses trained machine-learning models, which is a substantial analytic layer on top of the raw sequencing.
- Prescription and telehealth. Because the test is prescription-only, the price reflects a clinician reviewing your eligibility and ordering the test, plus results delivery through a telehealth path. That clinical oversight is part of what you are paying for.
- Panel breadth. The more cancers a panel screens for, the more the analysis has to do. Broader panels generally cost more than a focused one.
The number of cancers a panel targets is the lever most directly tied to price, and it is also the main choice you make. See how the LucenceINSIGHT panels differ below.
Does insurance cover a multi-cancer blood test? What about HSA or FSA?
For most people, insurance does not cover an MCED test today. These are newer, prescription-only laboratory-developed tests, and broad insurance coverage has not caught up to them. Treat an MCED test as an out-of-pocket screening choice unless your specific plan tells you otherwise.
The more useful news is that HSA and FSA funds are often eligible for prescription diagnostic tests, which can make the real cost meaningfully lower on an after-tax basis. Eligibility depends on your plan and the order details, so confirm with your plan administrator. Through Mito, non-member prices are $603.29 for LucenceINSIGHT Core, $1,056.89 for Me, and $1,812.89 for 12. Mito members, at $9 a month, pay $430.92, $754.92, and $1,294.92 respectively. All prices include the at-home blood draw at no additional cost and are HSA/FSA eligible. Confirm current pricing on each product page linked below.
How do you actually get one?
Because an MCED test requires a prescription, the path runs through a clinician rather than a self-serve checkout. With Mito, the flow is built around telehealth so you do not have to source your own doctor’s order:
- Choose a panel on the product page and start the order.
- Clinician review and order. A clinician reviews your information and, if the test is appropriate for you, places the order. This is also where anyone who is not a fit for the test gets caught. See the eligibility section in the multi-cancer early detection test guide.
- Blood draw. The test uses a standard blood draw. LucenceINSIGHT requires no fasting.
- Results through telehealth. Results come back through the telehealth path, and a positive signal is routed to the confirmatory workup your doctor decides on. LucenceINSIGHT’s turnaround is about 18 working days.
If you are a Mito member, an MCED signal does not sit in isolation. It lands alongside your standard bloodwork and the biomarkers Mito already tracks, so the Concierge and your consult can put a result in the context of the rest of your health picture rather than treating it as a one-off report.
Core, Me, or 12: how coverage scales
LucenceINSIGHT comes in three panels. The difference is breadth and personalization, and breadth maps to how much of US cancer mortality the panel’s targeted cancers account for.
- Core screens for signals associated with 6 cancers that together account for more than half of US cancer mortality: thyroid, breast, pancreatic, colorectal, lung, and liver.
- Me is Core plus 1 to 3 more cancers you choose with your doctor from a curated list, for 7 to 9 cancers total, personalized to your family history and personal risk.
- 12 is the comprehensive, gender-specific panel covering 12 cancers, the widest of the three.
The chart below shows how mortality coverage scales with breadth.
Panel | Cancers screened | Share of US cancer mortality covered | Best for |
|---|---|---|---|
LucenceINSIGHT Core | 6 | >50% | Essential first screen for the highest-mortality cancers |
LucenceINSIGHT Me | 7 to 9 | 53-76% (varies by selection) | Core plus cancers chosen to your personal and family risk |
LucenceINSIGHT 12 | 12 | ~78% | Comprehensive, gender-specific breadth |
Panel breadth and share of US cancer mortality covered. Coverage figures are conservative upper-limit estimates derived from GLOBOCAN 2024. Sensitivity varies by cancer type and stage; a cancer being on the panel does not mean it is equally detectable. Source: Lucence LucenceINSIGHT brochure; GLOBOCAN 2024.
How should you decide?
Breadth is not automatically better. A wider panel screens for more cancers, but prediction is imperfect, sensitivity varies by cancer and stage, and every result still has to translate into a next step you and your doctor would actually take. The Me panel exists precisely because the useful choice for most people is targeted: keep the highest-mortality cancers in Core, then add the ones your family history and personal risk actually point to.
A reasonable way to decide:
- Start with your risk. The Cancer Risk Profile quiz is a quick way to surface family history and lifestyle factors worth screening for.
- Match panel to risk. If you want a focused essential screen, Core fits. If specific cancers run in your family, Me lets you and your doctor add them. If you want the widest net, 12 is the gender-specific comprehensive option.
- Keep your guideline screening. Whatever you choose, mammography, colonoscopy, and other recommended screenings continue. MCED fills the gap they leave, it does not replace them.
- Plan for the finances. Budget for an out-of-pocket cost, and check whether your HSA or FSA can cover it.
For a step-by-step approach to building screening around your own risk, see the personalized cancer screening plan after 40.
Ready to look at panels and current pricing? Start with the personalized option, LucenceINSIGHT Me, or compare it with Core and 12. Mito also offers the Galleri multi-cancer early detection test if you want to compare options.
Multi-cancer blood test cost questions
How much does a multi-cancer blood test cost? It is priced well above routine bloodwork because of deep sequencing, machine-learning analysis, and prescription oversight, and the price rises with how many cancers the panel screens for. For current LucenceINSIGHT pricing, check the product pages, which stay up to date.
Does insurance cover it? Usually not today. These are newer prescription-only tests and broad insurance coverage has not caught up. Treat it as an out-of-pocket screening choice unless your plan says otherwise.
Can I use HSA or FSA? Often yes. Prescription diagnostic tests are frequently HSA/FSA eligible, which lowers the after-tax cost. Confirm with your plan administrator.
Do I need a doctor’s order? Yes. MCED tests are prescription-only. Mito’s telehealth path includes the clinician review and order, so you do not need to arrange your own.
Is a negative result the same as being cancer-free? No. A negative or low result does not rule out cancer, and a positive result is not a diagnosis. MCED complements guideline screening; it does not replace it.
Related reading
- What Is a Multi-Cancer Early Detection (MCED) Test?
- Multi-Cancer Early Detection Test Guide
- Personalized Cancer Screening Plan After 40
- Cancer Antigen 125 (CA-125)
Medical disclaimer
This article is for informational purposes only. It does not diagnose cancer, recommend a specific test for you, or replace medical care. Multi-cancer early detection is a screening test, not a diagnosis, and it complements rather than replaces guideline-recommended screening. A negative result does not mean you are cancer-free, and a positive result requires confirmatory evaluation ordered by a qualified clinician who considers your symptoms, history, and risk.
